Category «PHASE 3»

Nemorexant

It’s only fair to share… Nemorexant ACT-541468, UNII LMQ24G57E9 [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] LMQ24G57E9 Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- Originator Actelion Pharmaceuticals Developer Idorsia Pharmaceuticals Class Sleep disorder therapies Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists Phase III Insomnia 19 Oct 2018 Idorsia Pharmaceuticals plans a phase I trial for Liver disorders (Hepatic impairment) in November 2018 (PO) (NCT03713242) 09 Oct …

Molidustat

It’s only fair to share… Molidustat UNII-9JH486CZ13, cas no 1154028-82-6, MW: 314.3076 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Originator Bayer Schering Pharma Developer Bayer HealthCare Pharmaceuticals Class Antianaemics; Morpholines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules; Triazoles Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors Phase III Anaemia 24 Jun 2018 Biomarkers information updated 23 Jun 2018 Bayer initiates enrolment in the MIYABI HD-M phase III …

Revefenacin, ревефенацин , ريفيفيناسين , 瑞维那新 ,

It’s only fair to share… Revefenacin; 864750-70-9; TD-4208; UNII-G2AE2VE07O; G2AE2VE07O; TD-4208; GSK-1160724; 160724; GSK 1160724; TD-4028; YUPELRI Molecular Formula: C35H43N5O4 Molecular Weight: 597.76 g/mol [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate TD-4208 UNII:G2AE2VE07O ревефенацин [Russian] [INN] ريفيفيناسين [Arabic] [INN] 瑞维那新 [Chinese] [INN] Revefenacin is under investigation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Originator Theravance Developer Theravance Biopharma Class Antiasthmatics; Biphenyl compounds; Carbamates; Piperidines Mechanism of Action Muscarinic receptor …

Vericiguat, ベルイシグアト

It’s only fair to share… Vericiguat BAY 102; BAY-1021189; MK-1242 1350653-20-1 Chemical Formula: C19H16F2N8O2 Molecular Weight: 426.3878 Vericiguat; 1350653-20-1; UNII-LV66ADM269; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate; BAY-1021189; LV66ADM269 Methyl (4,6-diamino-2-(5-fluoro-1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl(pyrimidin-5-yl)carbamate methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate Methyl{4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridi- n-3-yl]pyrimidin-5-yl}carbamate Originator Bayer HealthCare Pharmaceuticals Developer Bayer HealthCare Pharmaceuticals; Merck & Co Mechanism of Action Guanylate cyclase stimulants Phase III Chronic heart failure Phase I Coronary artery disease 28 May 2018 Phase …

Vatiquinone, バチキノン

It’s only fair to share… Vatiquinone バチキノン Vatiquinone; Alpha-Tocotrienol quinone; EPI-743; UNII-6O85FK9I0X; 1213269-98-7; Vincerenone Molecular Formula: C29H44O3 Molecular Weight: 440.668 g/mol 2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione 2-((R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione 2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione 6O85FK9I0X 9604 Research Code:EPI-743; ATQ-3, BioE-743 MOA:Mitochondria Originator Edison Pharmaceuticals Developer Edison Pharmaceuticals; Sumitomo Dainippon Pharma; University of Florida; Yale University Class Alkadienes; Benzoquinones; Cyclohexenes; Small molecules Mechanism of Action Antioxidants; NQO1 modulators Orphan Drug Status Yes – Mitochondrial …

RG 7604,Taselisib

It’s only fair to share…      Molecular FormulaC24H28N8O2 Average mass460.531 Da RG7604,Taselisib GDC-0032, GDC0032;GDC 0032, RO5537381 1282512-48-4 [RN] 1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl- UNII:L08J2O299M 10.1021/jm4003632 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide NMR http://file.selleckchem.com/downloads/nmr/s710301-gdc-0032-hnmr-selleck.pdf POLYMORPHS almost A to Z, US9266903 Taselisib (GDC-0032) is an experimental cancer drug in development by Roche. Molecule is a complex heterocycle with no chiral centres, hazardous materials are used in synthesis, …

RG7440, Ipatasertib, アイパタセルチブ;

It’s only fair to share…   Ipatasertib GDC-0068 , RG7440 CAS 1001264-89-6, C24H32ClN5O2, 457.9962 アイパタセルチブ; イパタセルチブ; Antineoplastic, AKT serine/threonine kinase inhibitor 2(S)-(4-Chlorophenyl)-1-[4-[7(R)-hydroxy-5(R)-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(isopropylamino)propan-1-one (2S)-2-(4-Chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one 1-Propanone, 2-(4-chlorophenyl)-1-(4-((5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl)-1-piperazinyl)-3-((1-methylethyl)amino)-,  (2S)- Ipatasertib dihydrochloride 1396257-94-5 Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of Akt. It was discovered by Array Biopharma and is currently in phase II trials for treatment of breast …

BMS 986205, ONO 7701

It’s only fair to share… BMS 986205 (2R)-N-(4-Chlorophenyl)-2-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]propanamide Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-α-methyl-, cis- Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-α-methyl-, cis-(αR)- (i?)-N-(4-chlorophenyl)-2- c 5-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide CAS: 1923833-60-6 Phase III Head and neck cancer; Malignant melanoma BMS-986205, ONO-7701,  F- 001287 Molecular Formula C24H24ClFN2O Average mass 410.912 Da BMS986205, BMS 986205, ONO-7701 Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-α-methyl-, cis-(αR)- A potent and selective IDO1 (indoleamine 2,3-dioxygenase 1) inhibitor. Alternate Name (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide Appearance Crystalline solid CAS # 1923833-60-6 Molecular Formula …

ABL 001, Asciminib

It’s only fair to share…   ABL001 / Asciminib Cas 1492952-76-7 Chemical Formula: C20H18ClF2N5O3 Molecular Weight: 449.8428 Elemental Analysis: C, 53.40; H, 4.03; Cl, 7.88; F, 8.45; N, 15.57; O, 10.67 N-[4-[Chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)- PHASE 3, Chronic Myeloid Leukemia, NOVARTIS Asciminib is an orally bioavailable, allosteric Bcr-Abl tyrosine kinase inhibitor with potential antineoplastic activity. Designed to overcome resistance, ABL001 binds …

Alpelisib, BYL 719

It’s only fair to share… Alpelisib (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide PDT PAT WO 2010/029082 Chemical Names: Alpelisib; CAS 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719 Molecular Formula: C19H22F3N5O2S Molecular Weight: 441.473 g/mol alpelisib 1217486-61-7 BYL-719 BYL719 UNII-08W5N2C97Q BYL 719 Alpelisib (BYL719) (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide NVP-BYL719 Alpelisib is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT …